These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
128 related articles for article (PubMed ID: 36191975)
21. Clinical outcomes by relative docetaxel dose and dose intensity as chemotherapy for Japanese patients with castration-resistant prostate cancer: a retrospective multi-institutional collaborative study. Kamiya N; Suzuki H; Ueda T; Sato N; Nakatsu H; Mikami K; Sato N; Nomura K; Akakura K; Okano T; Ooki T; Naya Y; Ota S; Masai M; Ichikawa T Int J Clin Oncol; 2014 Feb; 19(1):157-64. PubMed ID: 23299278 [TBL] [Abstract][Full Text] [Related]
22. Hematopoiesis is prognostic for toxicity and survival of Leisser A; Nejabat M; Hartenbach M; Duan H; Shariat SF; Kramer G; Krainer M; Hacker M; Haug AR Hell J Nucl Med; 2017; 20 Suppl():157. PubMed ID: 29324927 [TBL] [Abstract][Full Text] [Related]
23. Review of Palliative Arays R; Ahmad Z; Howard L; Veselicky K; Kolodney J; SijinWen ; Hogan T J Nucl Med Technol; 2021 Mar; 49(1):70-74. PubMed ID: 33219158 [TBL] [Abstract][Full Text] [Related]
24. The efficacy of sequential therapy with docetaxel and cabazitaxel for castration-resistant prostate cancer: A retrospective multi-institutional study in Japan. Terada N; Sawada A; Kawanishi H; Fujimoto T; Magaribuchi T; Chihara I; Hashimoto K; Sakurai T; Shimizu Y; Uegaki M; Nakashima M; Narita S; Kubota M; Yamada Y; Tohi Y; Okabe K; Yatsuda J; Kamoto T Int J Urol; 2023 Feb; 30(2):227-234. PubMed ID: 36375045 [TBL] [Abstract][Full Text] [Related]
25. Administration of radium-223 and the prognosis in Japanese bone metastatic castration-resistant prostate cancer patients: A large database study. Kawahara T; Miyoshi Y; Ninomiya S; Sato M; Takeshima T; Hasumi H; Makiyama K; Uemura H Int J Urol; 2022 Sep; 29(9):1079-1084. PubMed ID: 35976620 [TBL] [Abstract][Full Text] [Related]
26. The Clinical Efficacy of Radium-223 for Bone Metastasis in Patients with Castration-Resistant Prostate Cancer: An Italian Clinical Experience. De Luca R; Costa RP; Tripoli V; Murabito A; Cicero G Oncology; 2018; 94(3):161-166. PubMed ID: 29241166 [TBL] [Abstract][Full Text] [Related]
27. Results From a Large, Multicenter, Retrospective Analysis On Radium223 Use in Metastatic Castration-resistant Prostate Cancer (mCRPC) in the Triveneto Italian Region. Maruzzo M; Basso U; Borsatti E; Evangelista L; Alongi F; Caffo O; Maines F; Galuppo S; De Vivo R; Zustovich F; Palleschi D; Zivi A; Sava T; Sorarù M; Iacovelli R; Nicodemo M; Baier S; Fratino L; Zagonel V Clin Genitourin Cancer; 2019 Feb; 17(1):e187-e194. PubMed ID: 30448106 [TBL] [Abstract][Full Text] [Related]
28. Radium-223 dichloride: a novel treatment option for castration-resistant prostate cancer patients with symptomatic bone metastases. McGann S; Horton ER Ann Pharmacother; 2015 Apr; 49(4):469-76. PubMed ID: 25573268 [TBL] [Abstract][Full Text] [Related]
29. Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial. Sartor O; Coleman R; Nilsson S; Heinrich D; Helle SI; O'Sullivan JM; Fosså SD; Chodacki A; Wiechno P; Logue J; Widmark A; Johannessen DC; Hoskin P; James ND; Solberg A; Syndikus I; Vogelzang NJ; O'Bryan-Tear CG; Shan M; Bruland ØS; Parker C Lancet Oncol; 2014 Jun; 15(7):738-46. PubMed ID: 24836273 [TBL] [Abstract][Full Text] [Related]
30. Hematologic Toxicity From Radium-223 Therapy for Bone Metastases in Castration-Resistant Prostate Cancer: Risk Factors and Practical Considerations. Jacene H; Gomella L; Yu EY; Rohren EM Clin Genitourin Cancer; 2018 Aug; 16(4):e919-e926. PubMed ID: 29678471 [TBL] [Abstract][Full Text] [Related]
31. Radium-223 in combination with docetaxel in patients with castration-resistant prostate cancer and bone metastases: a phase 1 dose escalation/randomised phase 2a trial. Morris MJ; Loriot Y; Sweeney CJ; Fizazi K; Ryan CJ; Shevrin DH; Antonarakis ES; Pandit-Taskar N; Deandreis D; Jacene HA; Vesselle H; Petrenciuc O; Lu C; Carrasquillo JA; Higano CS Eur J Cancer; 2019 Jun; 114():107-116. PubMed ID: 31082669 [TBL] [Abstract][Full Text] [Related]
32. Optimization of Radium-223 Treatment of Castration-resistant Prostate Cancer Based on the Burden of Skeletal Metastasis and Clinical Parameters. Shariftabrizi A; Kothari S; George S; Attwood K; Levine E; Lamonica D Oncologist; 2023 Mar; 28(3):246-251. PubMed ID: 36651837 [TBL] [Abstract][Full Text] [Related]
33. Radium-223 for metastatic, castration-resistant prostate cancer: A retrospective chart review study of real-world use in a tertiary hospital in Taiwan. Weng WC; Huang LH; Tseng NC; Ou YC J Formos Med Assoc; 2022 Oct; 121(10):1929-1937. PubMed ID: 35123846 [TBL] [Abstract][Full Text] [Related]
34. Bone-targeting radiopharmaceuticals for the treatment of bone-metastatic castration-resistant prostate cancer: exploring the implications of new data. Ryan CJ; Saylor PJ; Everly JJ; Sartor O Oncologist; 2014 Oct; 19(10):1012-8. PubMed ID: 25232039 [TBL] [Abstract][Full Text] [Related]
35. The influence of prior abiraterone treatment on the clinical activity of docetaxel in men with metastatic castration-resistant prostate cancer. Schweizer MT; Zhou XC; Wang H; Bassi S; Carducci MA; Eisenberger MA; Antonarakis ES Eur Urol; 2014 Oct; 66(4):646-52. PubMed ID: 24491307 [TBL] [Abstract][Full Text] [Related]
36. Disease Characteristics and Completion of Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer Treated With Radium-223 in an International Early Access Program. Saad F; Gillessen S; Heinrich D; Keizman D; O'Sullivan JM; Nilsson S; Miller K; Wirth M; Reeves J; Seger M; Carles J; Heidenreich A Clin Genitourin Cancer; 2019 Oct; 17(5):348-355.e5. PubMed ID: 31311763 [TBL] [Abstract][Full Text] [Related]
37. [Clinical study of long-term docetaxel based chemotherapy treatment for patients with castration-resistant prostate cancer]. Miyamae K; Kitani K; Hara K; Nakakuma K; Hamada Y; Yamasaki Y; Horio M; Miyamura S Nihon Hinyokika Gakkai Zasshi; 2014 Oct; 105(4):172-7. PubMed ID: 25757346 [TBL] [Abstract][Full Text] [Related]
38. Impact of treatment delay in Radium-223 therapy of metastatic castration-resistant prostate cancer patients. Fosbøl MØ; Petersen PM; Daugaard G; Holm S; Kjaer A; Mortensen J Ann Nucl Med; 2018 Jan; 32(1):16-21. PubMed ID: 28975586 [TBL] [Abstract][Full Text] [Related]
39. A randomised phase II trial of three dosing regimens of radium-223 in patients with bone metastatic castration-resistant prostate cancer. Sternberg CN; Saad F; Graff JN; Peer A; Vaishampayan UN; Leung E; Rosenbaum E; Gurney H; Epstein RJ; Davis ID; Wu B; Trandafir L; Wagner VJ; Hussain M Ann Oncol; 2020 Feb; 31(2):257-265. PubMed ID: 31959342 [TBL] [Abstract][Full Text] [Related]
40. Real-world outcomes of radium-223 dichloride for metastatic castration resistant prostate cancer. Kuppen MC; Westgeest HM; van der Doelen MJ; van den Eertwegh AJ; Coenen JL; Aben KK; van den Bergh AC; Bergman AM; den Bosch JV; Celik F; Hendriks MP; Lavalaye J; der Meer SV; Polee MB; Somford DM; van Oort IM; Uyl-de Groot CA; Gerritsen WR Future Oncol; 2020 Jul; 16(19):1371-1384. PubMed ID: 32469606 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]